Certara (NASDAQ:CERT) Price Target Lowered to $14.00 at Barclays

Certara (NASDAQ:CERT) had its price objective decreased by Barclays from $16.00 to $14.00 in a research report sent to investors on Friday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other research analysts also recently issued reports on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Certara in a research note on Wednesday, October 8th. UBS Group lowered their price objective on Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Craig Hallum assumed coverage on Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 target price on the stock. KeyCorp boosted their price target on Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Finally, Zacks Research raised Certara from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $15.38.

Certara Stock Down 23.1%

Shares of Certara stock traded down $2.60 during midday trading on Friday, hitting $8.67. The company had a trading volume of 9,104,388 shares, compared to its average volume of 1,604,633. Certara has a 52-week low of $8.47 and a 52-week high of $15.69. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.16 and a current ratio of 2.16. The stock has a market capitalization of $1.39 billion, a P/E ratio of 123.86 and a beta of 1.44. The company has a 50 day moving average of $11.77 and a 200 day moving average of $11.51.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. The firm had revenue of $104.62 million during the quarter, compared to the consensus estimate of $104.53 million. Certara had a return on equity of 5.17% and a net margin of 2.62%.During the same period last year, the company earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities analysts predict that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total value of $559,366.08. Following the transaction, the insider directly owned 73,979 shares of the company’s stock, valued at approximately $807,850.68. This trade represents a 40.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Certara

Institutional investors and hedge funds have recently modified their holdings of the stock. AdvisorNet Financial Inc bought a new stake in shares of Certara in the 2nd quarter worth about $25,000. First Horizon Corp bought a new position in shares of Certara during the third quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Certara in the first quarter valued at about $31,000. Versant Capital Management Inc increased its position in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares in the last quarter. Finally, AlphaQuest LLC purchased a new stake in Certara during the 1st quarter worth approximately $39,000. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.